It is well established that cisplatin-resistant cancer cells, including ovarian, lung, and colorectal cancer cells, show increased levels of GSH due to xCT overexpression and that xCT inhibition with sulfasalazine significantly improves sensitivity to cisplatin [55–57]. Here, SLC7A11 is linked to cancer.